<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855331</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-5</org_study_id>
    <nct_id>NCT04855331</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Versus Open Radical Pancreatectomy After Neoadjuvant Chemotherapy for Pancreatic Cancer</brief_title>
  <official_title>Minimally Invasive Versus Open Radical Pancreatectomy After Neoadjuvant Chemotherapy for Pancreatic Cancer: An Multicenter Open-label Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Third Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of University of South China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and effectiveness of minimally invasive&#xD;
      versus open radical pancreatectomy after neoadjuvant chemotherapy for pancreatic ductal&#xD;
      adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, the incidence of pancreatic ductal adenocarcinoma (PDAC) has been increasing&#xD;
      in the world. It has become the fourth leading cause of cancer death, and seriously threatens&#xD;
      human life. The surgical resection rate of PDAC is very low, only about 15% - 20% of the&#xD;
      patients can receive surgical treatment at the first visit. But at present, surgical&#xD;
      resection is still the only treatment that can make the PDAC patients survive for a relative&#xD;
      long time. (CA Cancer J Clin. 2016;66(1):7) With the application of neoadjuvant chemotherapy&#xD;
      in clinical practice, the treatment concept of PDAC has changed significantly. A growing&#xD;
      number of studies show that neoadjuvant chemotherapy can significantly improve the radical&#xD;
      resection (R0) rate of PDAC patients, and thus improve the prognosis (J Clin Oncol.&#xD;
      2017;35(5):515; J Surg Oncol. 2019;120(6):976). Currently, according to the latest edition of&#xD;
      the National Comprehensive Cancer Network (NCCN) guidelines, patients with resectable&#xD;
      pancreatic cancer (RPC) with high risk factors, borderline resectable pancreatic cancer&#xD;
      (BRPC) with good physical condition, and locally advanced pancreatic cancer (LAPC) with&#xD;
      tolerable general condition, should receive neoadjuvant chemotherapy.&#xD;
&#xD;
      With the development of pancreatic surgery, the mortality has decreased from 30% to 3-5%.&#xD;
      Minimally invasive technique has the advantages of less intraoperative bleeding, less&#xD;
      postoperative pain, less postoperative complications and relatively high cost-effectiveness.&#xD;
      In other abdominal tumors, such as gastric and colorectal cancer, minimally invasive&#xD;
      technique has been recommended as the first choice for radical operation (Gastroenterol Res&#xD;
      Pract, 2017,2017:9278469; Surg Clin North Am, 2017,97(3):54). Minimally invasive pancreatic&#xD;
      surgery is mainly composed of minimally invasive pancreatoduodenectomy (MIPD) and minimally&#xD;
      invasive distal pancreatectomy (MIDP). With the progress of surgical technique, especially&#xD;
      the maturity of laparoscopic or robotic vascular resection and reconstruction, MIPD becomes&#xD;
      safe and feasible, and has been carried out in large pancreatic surgery centers. On the other&#xD;
      hand, MIDP is the main indication of minimally invasive pancreatic surgery because it does&#xD;
      not need digestive tract reconstruction, has no complex anastomosis, and involves less large&#xD;
      vessels. Compared with open pancreatic surgery, MIDP has the advantages of less&#xD;
      intraoperative bleeding and faster postoperative recovery, and there was no significant&#xD;
      difference in the incidence of pancreatic fistula, total complication rate and mortality (Ann&#xD;
      Surg. 2019;269(1):2; Updates Surg. 2020;72(2):387).&#xD;
&#xD;
      Neoadjuvant chemotherapy can help to reduce tumor stage, alleviate vascular invasion, improve&#xD;
      R0 resection rate, control tumor micro-metastasis and reduce tumor recurrence and metastasis&#xD;
      risk. With the recommendations of clinical guidelines, patients with PDAC receiving&#xD;
      neoadjuvant chemotherapy is increasing. For these patients, how to choose the further&#xD;
      surgical strategy and whether minimally invasive surgery is safe and effective compared with&#xD;
      open surgery have not been reported.&#xD;
&#xD;
      Therefore, we designed this multicenter randomized controlled trial to assess the safety and&#xD;
      effectiveness of minimally invasive versus open radical pancreatectomy after neoadjuvant&#xD;
      chemotherapy for PDAC. This study will provide high-level evidence-based medicine for the&#xD;
      choice of surgical strategy for PDAC after neoadjuvant chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>90 days after the surgery</time_frame>
    <description>The length of hospital stay from the end of surgery to discharge or death. The length of hospital stay for readmission after discharge is not included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>90 days after the surgery</time_frame>
    <description>The specific postoperative complications of pancreatic surgery include postoperative pancreatic fistula, postoperative hemorrhage and gastroparesis. Other common postoperative complications include abdominal infection, incision nonunion and so on. The degree of complications was evaluated by Clavien-Dindo grading system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>1 day</time_frame>
    <description>The time from the beginning to the end of the surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>30 days after the surgery</time_frame>
    <description>Postoperative pathology confirmed that there were no tumor cells in the tissue within 1 mm from the surgical margin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 30 days readmission rate</measure>
    <time_frame>90 days after the surgery</time_frame>
    <description>The rate of rehospitalization within 30 days after surgery due to aggravation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 90 days mortality rate after operation</measure>
    <time_frame>90 days after the surgery</time_frame>
    <description>The mortality within 90 days after surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>up to 5 years after the surgery</time_frame>
    <description>The time from surgery until tumor recurrence, death or the last follow-up time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years after the surgery</time_frame>
    <description>The time from surgery until death or the last follow-up time.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Minimally invasive radical pancreatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent laparoscopic or robotic radical pancreatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open radical pancreatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent open radical pancreatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive radical pancreatectomy</intervention_name>
    <description>The tumor was completely removed by minimally invasive radical pancreatectomy. Routine lymph node dissection was performed and no tumor cells could be observed by microscope in the tissue within 1 mm from the resection margin (R0 resection).</description>
    <arm_group_label>Minimally invasive radical pancreatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open radical pancreatectomy</intervention_name>
    <description>The tumor was completely removed by minimally invasive radical pancreatectomy. Routine lymph node dissection was performed and no tumor cells could be observed by microscope in the tissue within 1 mm from the resection margin (R0 resection).</description>
    <arm_group_label>Open radical pancreatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Before neoadjuvant chemotherapy, pancreatic ductal adenocarcinoma was confirmed by&#xD;
             pathology;&#xD;
&#xD;
          -  According to the guidelines, neoadjuvant chemotherapy should be performed before&#xD;
             surgery, including patients with resectable pancreatic cancer (RPC) with high risk&#xD;
             factors, borderline resectable pancreatic cancer (BRPC) with good physical condition,&#xD;
             and locally advanced pancreatic cancer (LAPC) with tolerable general condition;&#xD;
&#xD;
          -  Receive at least 2 cycles of neoadjuvant chemotherapy before radical surgery；&#xD;
&#xD;
          -  After neoadjuvant chemotherapy, the patient can be further treated by minimally&#xD;
             invasive or open surgery;&#xD;
&#xD;
          -  No obvious surgical contraindications, suitable for minimally invasive surgery;&#xD;
&#xD;
          -  ECOG score of preoperative physical condition was 0-1;&#xD;
&#xD;
          -  No history of preoperative pancreatitis;&#xD;
&#xD;
          -  Preoperative PET-CT or other imaging examination did not show distant metastasis;&#xD;
&#xD;
          -  The expected postoperative survival time was more than 3 months;&#xD;
&#xD;
          -  Be able to comply with research protocol, follow-up plan and other protocol&#xD;
             requirements;&#xD;
&#xD;
          -  Voluntary participation and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoadjuvant chemotherapy is not suitable before operation according to the guidelines;&#xD;
&#xD;
          -  Invasion of adjacent organs, abdominal cavity or distant metastasis was found by&#xD;
             introperative exploration;&#xD;
&#xD;
          -  Patients requiring total pancreatectomy;&#xD;
&#xD;
          -  Severe impairment of heart, liver and kidney function;&#xD;
&#xD;
          -  Patients with other malignancies or hematological diseases;&#xD;
&#xD;
          -  The patient is pregnant, planning to be pregnant or lactating；&#xD;
&#xD;
          -  Before surgery, anti-cancer therapy except neoadjuvant chemotherapy were performed,&#xD;
             including interventional chemoembolization, ablation, radiotherapy and molecular&#xD;
             targeted therapy;&#xD;
&#xD;
          -  Participants in other clinical trials;&#xD;
&#xD;
          -  Tumor progression occurred in RPC or BRPC patients during neoadjuvant chemotherapy.&#xD;
             After neoadjuvant chemotherapy, LAPC patients failed reach the standard of minimally&#xD;
             invasive surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianjun Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianjun Yu, MD, PhD</last_name>
    <phone>+86-13801669875</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zheng Li, MD</last_name>
    <phone>+86-18521097686</phone>
    <email>reclusion@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XianJun Yu, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
    <investigator>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol. 2017 Feb 10;35(5):515-522. doi: 10.1200/JCO.2016.68.5081. Epub 2016 Sep 30.</citation>
    <PMID>27621388</PMID>
  </reference>
  <reference>
    <citation>Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM, Smoot RL, Chari ST, Carter RE, Kendrick ML. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. J Surg Oncol. 2019 Nov;120(6):976-984. doi: 10.1002/jso.25681. Epub 2019 Aug 26.</citation>
    <PMID>31452208</PMID>
  </reference>
  <reference>
    <citation>Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G; Dutch Pancreatic Cancer Group. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.</citation>
    <PMID>32105518</PMID>
  </reference>
  <reference>
    <citation>Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4.</citation>
    <PMID>29625841</PMID>
  </reference>
  <reference>
    <citation>Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705.</citation>
    <PMID>29462005</PMID>
  </reference>
  <reference>
    <citation>Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg. 2019 Aug;270(2):340-347. doi: 10.1097/SLA.0000000000002753.</citation>
    <PMID>29596120</PMID>
  </reference>
  <reference>
    <citation>Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, López-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294. doi: 10.1016/S2468-1253(19)30327-9. Epub 2020 Jan 14.</citation>
    <PMID>31953079</PMID>
  </reference>
  <reference>
    <citation>de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn E, Dijkgraaf M, van Eijck C, Festen S, Gerhards M, Groot Koerkamp B, de Hingh I, Kazemier G, Klaase J, de Kleine R, van Laarhoven C, Luyer M, Patijn G, Steenvoorde P, Suker M, Abu Hilal M, Busch O, Besselink M; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial. Ann Surg. 2019 Jan;269(1):2-9. doi: 10.1097/SLA.0000000000002979.</citation>
    <PMID>30080726</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>President of Shanghai Pancreatic Cancer Institute</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Minimally Invasive Pancreatectomy</keyword>
  <keyword>Safety and Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

